Piramal Pharma has announced its standalone and consolidated results for the First Quarter (Q1) ended June 30, 2026.

Exceptional items in Q1FY26 include one-time insolvency proceeds received from a claim filed against a third-party supplier of our complex hospital generics business, with the NCLT in November 2023.

Nandini Piramal, Chairperson, Piramal Pharma, said, "We have started FY27 on a strong note, with all 3 businesses delivering mid-to-high teens revenue growth alongside meaningful EBITDA margin expansion. Our CDMO business delivered broadbased growth across India and overseas sites, supported by an enhanced commercial team, healthy RFP activity and order inflows, and strong execution. In Complex Hospital Generics, we maintained leadership in key therapies, gained traction in ex-US inhalation anesthesia markets, and continued progression on integration of Kenalog. Our Consumer Healthcare business delivered yet another quarter of robust growth, driven by Power Brands, e-commerce, wider distribution, premiumisation, and disciplined brand investments.

Encouraged by this momentum, we look forward to delivering sustained revenue growth and EBITDA expansion through FY27, while staying agile amid a dynamic external environment."